Recent advances into the molecular understanding of RCC have contributed to the development of novel molecularly targeted therapeutics such as VEGF-antibody and small molecules interfering with tyrosine kinase receptors and mammalian target of rapamycin (mTOR) [32, 33]. The gene discussed is VEGFA; the disease is renal cell carcinoma.